Market Research Report

Japan Healthcare Market Key Takeaways

• The Japan Healthcare Market size was valued at USD 236.6 million in 2025 and is projected to grow from USD 250.26 million in 2026 to USD 347.9 million by 2032, exhibiting a CAGR of 11.45% during the forecast period.
• Out of Japan’s total population of approximately 124 million, an estimated 3.6 million individuals were living with cardiovascular diseases (CVD).
• Out of every 1,000 individuals in Japan in 2025, approximately 8–9 people were newly diagnosed with cancer annually, as over 1 million new cancer cases are reported each year, reflecting its significant burden.
• Japan’s healthcare system is supported by a workforce of 2.6 physicians and 12.2 nurses per 1,000 populations, alongside 8,122 hospitals and approximately 1.48 million hospital beds. The country also maintains one of the world’s highest diagnostic capacities, with 184 advanced imaging units per million populations, enabling efficient and technology-driven healthcare delivery.

Japan Healthcare Market Size and Outlook

The Japan healthcare industry size was valued at USD 236.6 million in 2025 and is projected to grow from USD 250.26 million in 2026 to USD 347.9 million by 2032. Along with this, the market is estimated to grow at a CAGR of around 11.45% during the forecast period, i.e., 2026-32.

The Healthcare industry in Japan continues to demonstrate structural resilience, supported by a rapidly aging population and sustained public investment. According to Japan’s Ministry of Health, Labour and Welfare (MHLW), over 29.78% of the population is aged 65 and above in 2025, driving demand for chronic and long-term care services.

Disease burden patterns are shifting toward complex and high-cost conditions, particularly diabetes, dementia, and rare genetic disorders. Japan has identified more than 348 designated intractable diseases under its national registry system, enabling structured funding and research support. The government’s “Data Health Reform” initiative is accelerating integration of electronic health records and real-world data to improve diagnosis and treatment efficiency. In addition to this, institutional end users, including public hospitals and university medical centers, dominate demand by adopting advanced diagnostic systems and specialty care programs, while long-term care facilities are expanding capacity to address rising elderly patient dependency. Electronic health records (EHRs) across multiple hospitals have already been established, covering 870,000 patients , demonstrating active use of real-world data for clinical research and treatment improvement.

On the supply side, Japan’s pharmaceutical and biotechnology ecosystem is anchored in major hubs such as Tokyo, Osaka, and Kanagawa, where companies are advancing precision medicine and regenerative therapies. The Pharmaceuticals and Medical Devices Agency (PMDA) has strengthened fast-track approval pathways for innovative drugs, reducing review timelines for breakthrough therapies. In 2025, Japan expanded subsidies for domestic drug manufacturing under its economic security policies, encouraging localization of critical medicines. For instance, in July 2025, Teijin Limited subsidiaries were selected for a government subsidy program supporting CDMO expansion for regenerative, cell, and gene therapy manufacturing.

Technological transformation remains central to future growth, particularly through artificial intelligence and digital health integration. Japan has increased public investment in artificial intelligence and digital infrastructure, including approximately USD 1.6 billion allocated in 2025 for AI development, alongside expanded government support for healthcare digitalization initiatives such as AI-based diagnostics, electronic health records, and care robotics. These combined efforts position Japan’s healthcare sector for sustained growth through 2032, driven by innovation, policy support, and demographic necessity.

Japan Healthcare Market Scope

Japan Healthcare Industry Growth Drivers

Rising Inbound Medical Tourism for Advanced Procedures Expanding Japan’s Healthcare Service Volumes

Japan’s healthcare market is increasingly driven by the rise in inbound medical tourism, particularly for advanced diagnostics and high-precision treatments. This trend has strengthened post-pandemic as the government actively promotes the country as a destination for high-quality care under its medical tourism facilitation policies. According to the Japan National Tourism Organization, inbound visitors surpassed 42.7 million in 2025, with a growing segment seeking health checkups and specialized treatments, especially from other Asian economies .

This influx is directly translating into higher service demand across private hospitals, specialty clinics, and diagnostic centers. Data from Japan’s Ministry of Economy, Trade, and Industry indicates that the number of medical institutions accepting foreign patients has expanded significantly, supported by multilingual services and dedicated international patient departments. High-value services such as oncology screening, cardiovascular procedures, and comprehensive health checkups are witnessing rising uptake, contributing disproportionately to revenue and utilization growth within urban healthcare hubs. Tokyo hospitals treated 3,283 foreign patients, up sharply from 624, reflecting a strong post-pandemic increase.

Crucially, medical tourism is expanding total market volume by adding new patient inflows rather than redistributing domestic demand. Policy measures introduced in 2025, including streamlined medical visas and public-private partnerships to internationalize healthcare services, are reinforcing this trend. As foreign patients typically opt for premium and bundled care services, they drive higher throughput in specialized segments without burdening public systems. This sustained external demand stream is positioning medical tourism as a structurally additive growth driver for Japan’s healthcare market.

Recent Trends

AI-Driven Drug Discovery Platforms Reshaping Japan’s Pharmaceutical Innovation Model

Japan’s pharmaceutical sector is undergoing a structural transformation through the rapid integration of AI-driven drug discovery platforms, shifting from linear R&D to data-centric, predictive innovation. This trend has accelerated due to rising development costs and low success rates, prompting firms to adopt AI for target identification and molecule design. Government-backed initiatives, including the 2025 Healthcare Policy Phase III, explicitly prioritize advanced drug discovery and commercialization support. Additionally, collaborative AI models trained on shared datasets from over 16 pharmaceutical companies highlight a national push toward ecosystem-based innovation.

This transition is fundamentally altering industry dynamics by embedding AI across the entire drug development value chain, from early discovery to clinical decision-making. In 2026, Takeda entered a USD 1.7 billion partnership with Iambic Therapeutics to leverage AI for oncology and gastrointestinal drug development, utilizing advanced platforms to predict protein–molecule interactions. This follows Takeda’s AI-assisted drug zasocitinib achieving successful late-stage clinical trial results in 2025, demonstrating that AI-generated candidates are progressing beyond research into regulatory pathways.

Additionally, companies like Astellas are collaborating with domestic research institutions to scale AI-driven innovation, while Chugai’s partnership with Gero of USD 250 million focuses on identifying novel targets for age-related diseases, reflecting the diversification of AI applications . The momentum is expected to persist as Japan aligns corporate investment with ecosystem development and global collaboration. Continued high-value deals, clinical validation, and cross-border data integration indicate that AI-driven drug discovery is becoming a core, long-term pillar of Japan’s pharmaceutical competitiveness.

Opportunities and Challenges

Lagging Digital Transformation Creating Scalable Opportunities for Digital Health and AI Integration in Japan

Japan’s healthcare system continues to face a structural challenge due to the slow adoption of electronic health records and interoperable systems, despite strong policy intent. Government data indicates that as of 2023, only around 55% of clinics and 65% of hospitals had adopted EHR systems, reflecting persistent resistance to workflow changes and high implementation costs. This fragmentation limits data accessibility and slows the integration of advanced technologies such as AI and remote monitoring.

However, this gap is actively generating a large-scale market opportunity supported by aggressive government intervention. Telemedicine adoption has surged significantly since COVID-19, with remote consultations expanding rapidly, further reinforcing the need for integrated digital platforms.

This opportunity is particularly favorable for new entrants offering cost-effective, cloud-based, and interoperable solutions. Companies such as PHC Group have launched cloud-native EMR systems targeting smaller clinics, demonstrating strong market traction . As policy support and unmet demand converge, digital health providers are well-positioned to scale rapidly. This creates a unique entry advantage for agile players in the Japanese healthcare industry, who can deliver flexible, cost-efficient solutions aligned with evolving Japanese healthcare market trends 2026–2032.

Epidemiology Profile

Cancer:

Cancer prevalence in Japan is high, largely driven by the country’s rapidly aging population, with incidence rates continuing to rise across major cancer types such as lung, colorectal, and gastric cancers. Although mortality remains considerable and cancer is the leading cause of death, outcomes are gradually improving due to widespread early detection programs and advances in treatment options. Key risk factors, including smoking, dietary habits, and genetic susceptibility, continue to pose ongoing public health challenges.

At the same time, Japan’s strong diagnostic infrastructure and improved therapeutic effectiveness have contributed to longer survival periods, which also increases the overall number of people living with cancer. As a result, the total patient burden is steadily expanding, and the number of cancer patients is projected to reach around 2 million among both men and women in the 2030s. Overall, the high prevalence reflects not only rising incidence but also better detection and improved survival outcomes, which together are extending patient lifespans and intensifying the long-term healthcare burden.

In terms of incidence, Japan records nearly 979,300 new cancer cases annually, making it one of the highest contributors to new disease burden in the country. The incidence rate is approximately 558,300 males and 421,000 females, with common cancers including stomach, colorectal, lung, breast, and prostate cancer. This steady inflow of new cases is strongly linked to demographic aging, lifestyle factors, and long-term exposure risks such as smoking and dietary patterns.

Cancer also remains the leading cause of death in Japan, accounting for roughly 393,100 deaths annually or about 26–27% of all deaths. Despite improvements in screening and treatment, mortality remains high due to late-stage detection in elderly patients and the high prevalence of aggressive cancer types. Together, these indicators highlight cancer as a structurally dominant disease in Japan’s healthcare system, shaping long-term policy, oncology investment, and healthcare infrastructure expansion.

Japan’s treatment landscape represents one of the most advanced oncology treatment markets globally, characterized by a highly structured healthcare system, rapid adoption of innovative therapies, and strong government support for precision medicine. Its cancer treatment leadership is exemplified by AI-driven innovations such as Sumitomo Corporation’s investment in AiRato Inc., which develops AI-powered radiation therapy planning software. This reduces planning time dramatically and enhances precision, positioning Japan as a hub for digital oncology solutions. Such corporate investment reflects strong demand for efficiency and accuracy in cancer care.

National Cancer Center Japan (NCC) launched LC-SCRUM-CD, a nationwide clinical trial network involving 150 hospitals, to accelerate precision medicine for cancer patients. This program integrates genomic profiling into treatment decisions, ensuring therapies are tailored to individual patients. Pharmaceutical firms are investing heavily in checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, with adoption across lung, breast, and colorectal cancers. Therefore, by combining cutting-edge technology with nationwide initiatives and sustained R&D funding, Japan has established itself as a global leader in cancer treatment, ensuring both improved patient outcomes and long-term market dominance.

Cardiovascular Diseases:

Cardiovascular diseases remain the most dominant chronic disease burden in Japan, primarily driven by their high prevalence and mortality among a rapidly ageing population. Cardiovascular diseases remain a dominant chronic disease burden in Japan, with mortality rate acting as the leading segment due to high absolute deaths despite improved survival outcomes.

CVDs account for nearly 28% of total deaths in Japan, making them one of the top causes of national mortality.

This structural demographic shift ensures mortality rate remains the most influential segment within the cardiovascular disease landscape. The prevalence is structurally high due to Japan’s world-leading life expectancy, which increases the proportion of elderly individuals living with long-term cardiac conditions. Incidence continues to be influenced by persistent risk factors such as hypertension, high salt intake in diet, smoking history among older cohorts, and increasing metabolic disorders, including diabetes. Government-led preventive programs under universal health coverage support early screening and long-term disease management across cardiac conditions .

Technological advancement and precision-driven care are fundamentally transforming the cardiovascular treatment landscape in Japan, positioning it as one of the most advanced and integrated systems globally. Artificial intelligence has been increasingly integrated into cardiovascular diagnostics in Japan, with AI-enhanced electrocardiography (ECG) emerging as a key application in real-world clinical settings. Population-based screening programs in cities such as Shimizu have demonstrated the use of AI-ECG for early detection of atrial fibrillation risk before symptom onset, and through collaboration with Vista AI, hospitals across Japan are deploying automated cardiac MRI workflow optimization, leveraging Japan’s high MRI equipment density for cardiovascular diagnostics .

Japan’s cardiovascular treatment ecosystem is supported by a strong policy framework led by the Stroke and Cardiovascular Disease Control Act, complemented by a national CVD plan and prefectural-level implementation strategies that ensure integrated care delivery across acute treatment, rehabilitation, and long-term management, while nationwide screening programs and preventive policies such as Health Japan 21 strengthen early diagnosis and sustained treatment pathways, collectively enhancing clinical outcomes and reducing long-term disease burden.

Japan Healthcare Market News and Recent Developments

2026: Japan Approves the World’s First Treatment Made with Reprogrammed Human Cells

Japan’s approval of the world’s first therapies derived from induced pluripotent stem (iPS) cells represents a breakthrough in clinical medicine and marks the transition of regenerative therapies from experimental research to real-world application. The approved treatments include cell-based solutions for conditions such as severe heart failure and Parkinson’s disease, where lab-grown cells are used to repair or replace damaged tissue. Unlike conventional therapies that primarily manage symptoms, these iPS-based treatments aim to restore biological function at a cellular level. The approval has been granted under a conditional framework, allowing controlled clinical use while additional long-term safety and efficacy data continue to be collected, reflecting Japan’s progressive regulatory approach toward advanced therapies.

Impact Analysis: From a market perspective, this development is expected to significantly reshape the healthcare landscape by introducing a new high-value segment centered on regenerative medicine. It is likely to accelerate investment flows into biotechnology, particularly in stem cell research, cell manufacturing infrastructure, and precision medicine platforms. Pharmaceutical companies may increasingly shift focus toward curative therapies, while hospitals will require specialized infrastructure and expertise to administer such treatments. At the same time, Japan’s early regulatory approval positions it as a global leader in regenerative medicine, attracting international collaborations and strengthening its competitive advantage. However, high treatment costs, limited large-scale clinical data, and scalability challenges may initially constrain widespread adoption, though long-term growth potential remains substantial.

2026: Rakuten Medical Raises USD100 Million in Fundraising Round

The recent funding announcement involving Rakuten Medical, which raised USD 100 million in a Series F round, reflects strong global investor confidence in Japan’s advanced oncology innovation pipeline. The company is developing a novel cancer treatment platform known as photoimmunotherapy (Alluminox), which combines a targeted drug with a light-activated mechanism to selectively destroy cancer cells while minimizing damage to surrounding tissue. Rakuten Group–backed Rakuten Medical has already commercialized this therapy in Japan for head and neck cancer and is currently advancing a global Phase 3 clinical trial to expand its use and seek regulatory approval in international markets, including the United States, by 2028. The funding will primarily be used to accelerate clinical trials, expand operational capabilities, and support global regulatory submissions.

Impact Analysis: From a market perspective, this development signals a significant shift toward next-generation, targeted cancer therapies and reinforces Japan’s position as a global innovation hub in oncology. The successful fundraising exceeding initial targets indicates strong investor appetite for precision medicine and device-drug combination therapies, which are expected to redefine cancer treatment protocols. Additionally, the fact that the therapy is already approved and commercialized in Japan provides a “proof-of-concept market,” strengthening Japan’s role as a testing ground for advanced therapies before global expansion. The investment is also likely to accelerate growth in associated segments such as medical devices (laser systems), clinical trial infrastructure, and biopharmaceutical R&D. Overall, this funding round highlights the increasing convergence of biotechnology, medical devices, and immunotherapy, positioning Japan at the forefront of innovation-driven cancer treatment development.

2024: SoftBank–Tempus AI Partnership for Precision Oncology in Japan

The joint venture between SoftBank Group and Tempus AI marks a significant step toward integrating artificial intelligence into cancer treatment in Japan. The collaboration focuses on leveraging large-scale clinical and genomic data to generate personalized treatment recommendations for cancer patients, using AI-driven analytics already deployed in the United States. The initiative aims to bring advanced precision medicine capabilities to Japan by enabling clinicians to match patients with targeted therapies and clinical trials based on individual genetic profiles.

Impact Analysis: From a market perspective, this development is expected to accelerate the adoption of precision oncology and data-driven treatment models in Japan. The integration of AI with genomic data will improve treatment accuracy, reduce trial-and-error prescribing, and enhance patient outcomes, particularly in complex cancers. Additionally, it strengthens Japan’s position in the high-growth precision medicine segment and encourages investment in digital health infrastructure, data platforms, and AI-based clinical decision systems. However, widespread adoption will depend on data integration, regulatory alignment, and physician acceptance, though long-term impact on oncology treatment innovation remains highly significant.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.